News
AIM
0.5620
-8.48%
-0.0521
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. Is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. The next CEO Corner segment has been published on the company's website. The CEO Corner Segment includes a discussion of Ampligen and Keytruda in ovarian cancer.
Dow Jones · 3d ago
Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab
NASDAQ · 4d ago
AIM IMMUNOTECH ANNOUNCES POSITIVE TOP-LINE, PROTOCOL-PLANNED INTERIM REPORT DATA FROM THE STUDY OF AMPLIGEN COMBINED WITH PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT OVARIAN CANCER
Reuters · 4d ago
Weekly Report: what happened at AIM last week (0401-0405)?
Weekly Report · 6d ago
Ampligen’s Prospects in Post-COVID Fatigue and Cancer Treatment: A Strong Buy Recommendation
TipRanks · 04/03 19:05
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
AIM ImmunoTech reports quarterly losses of $0.26 per share. The company reported quarterly sales of $65.00 thousand. Missed the analyst consensus estimate of $40.50 thousand by 62.50%. The company also reported quarterly losses for the same period last year.
Benzinga · 04/03 02:58
AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023
AIM ImmunoTech reported earnings per share of -26 cents for the fourth quarter of 2023. The company reported revenue of $65,000. This was 62.50% better than the analyst estimate for revenue in the same period. AIM immunoTech just reported results.
Investorplace · 04/02 15:52
AIM ImmunoTech GAAP EPS of -$0.60, revenue of $0.2M
Seeking Alpha · 04/02 11:34
AIM IMMUNOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 04/02 11:30
Earnings Scheduled For April 2, 2024
Ocugen is estimated to report earnings for its fourth quarter. Allego is projected to report quarterly loss at $0.04 per share on revenue of $83.79 million. Cal-Maine Foods is expected to report fourth quarter earnings at $2.46 per share.
Benzinga · 04/02 10:25
Navigating the Future: Aim Immunotech’s Challenge Against Rapid Tech Evolution in Pharma
TipRanks · 04/02 06:00
Preview: AIM ImmunoTech's Earnings
AIM ImmunoTech will release its quarterly earnings report on Tuesday, 2024-04-02. The company is expected to report an earnings per share of $-0.15. Shares of AIM immunoTech were trading at $0.471 as of March 29.
Benzinga · 04/01 18:05
AIM ImmunoTech FY 2023 Earnings Preview
AIM ImmunoTech is scheduled to announce FY earnings results on Tuesday, April 2nd. The consensus EPS estimate is -$0.50 and the consensus revenue estimate is $0.16M. AIM has beaten revenue estimates 50% of the time in the last year.
Seeking Alpha · 04/01 17:48
Notable earnings before Tuesday's open
Seeking Alpha · 04/01 13:48
Weekly Report: what happened at AIM last week (0325-0329)?
Weekly Report · 04/01 10:23
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech will present at the MedInvest Biotech & Pharma Investor Conference in New York, N.Y., on April 3, 2024. Thomas K. Equels, MS JD, will be the Chief Executive Officer of AIM. AIM will be presenting at the conference.
Barchart · 03/28 07:05
Earnings Scheduled For March 26, 2024
Bluebird bio is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. AIM ImmunoTech is estimated to report earnings for its fourth quarter. Elbit Systems is projected to report. Quarterly earnings at $1.38 per share.
Benzinga · 03/26 08:47
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. Will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on April 2, 2024. The conference call will be held at 8:30am ET on Tuesday, April 2.
Barchart · 03/26 08:05
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed lower by over 300 points on Friday. Recent notable insider transactions for penny stocks include Citizens, Inc. And Brightcove Inc. Power Solutions International and AIM ImmunoTech are among the companies with recent insider transactions.
Benzinga · 03/25 10:33
Weekly Report: what happened at AIM last week (0318-0322)?
Weekly Report · 03/25 10:25
More
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.